[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

详细信息    查看全文

• 作者：Evelyn E. C. de Jong ; Wouter van Elmpt…
• 关键词：[18F]FDG PET/CT ; Response assessment ; Nitroglycerin ; Bevacizumab ; Stage IV NSCLC
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：44
• 期：1
• 页码：8-16
• 全文大小：793KB
• 刊物类别：Medicine
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1619-7089
• 卷排序：44

文摘

PurposeNitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. And we compared the [18F]FDG PET response assessment to RECIST response assessment and survival.